To circumvent aGVHD in the early phase after allogeneic stem cell transplantation but to provide GVL activity later on, we performed alloPBSCT with CD34 3 However, this benefit is counterbalanced by an increased risk of engraftment failure 4 as well as of relapse of the underlying disease (at least in CML) due to impaired T cell-mediated GVL activity. 5, 6 In order to escape from this dilemma, we performed allogeneic PBSCT by transplanting a CD34 + selected, eg T cell-depleted graft followed by a delayed add-back of CD3 + donor-derived T cells. Our aims were to avoid acute GVHD during the early phase after allo PBSCT, but to provide stable engraftment, sufficient immunocompetence, and GVL activity later on. Study endpoints were efficiency of T cell depletion/CD34
/kg CD3
؉ cells while CsA had been tapered to 50% of the starting dose. One of these patients died after a second T cell boost given on day +90 without concomitant immunosuppression due to grade IV intestinal aGVHD. Three others developed cutaneous cGVHD. Taken together, T cell depletion by CD34 ؉ selection does not impair rapid engraftment in the HLA-identical sibling donor setting. Using standard-dose CsA the risk for acute GVHD seems to be minimized. Add-back of 2 × 10 6 /kg CD3 ؉ cells on day +60 with CsA protection is feasible. However, whether this is the optimal time point and number of T cells remain to be further elucidated. Bone Marrow Transplantation (2000) 25, Suppl. 2, S2-S5.
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3 However, this benefit is counterbalanced by an increased risk of engraftment failure 4 as well as of relapse of the underlying disease (at least in CML) due to impaired T cell-mediated GVL activity. 5, 6 In order to escape from this dilemma, we performed allogeneic PBSCT by transplanting a CD34 + selected, eg T cell-depleted graft followed by a delayed add-back of CD3 + donor-derived T cells. Our aims were to avoid acute GVHD during the early phase after allo PBSCT, but to provide stable engraftment, sufficient immunocompetence, and GVL activity later on. Study endpoints were efficiency of T cell depletion/CD34
+ selection, kinetics of engraftment, incidence of aGVHD, and feasibility of delayed add-back of CD3 + cells.
Patients and methods

Demographic data
Ten consecutive patients were included on to the trial. Five of them fullfilled standard eligibility criteria for allogeneic transplantation, whereas five others were high risk patients according to disease status (one second myeloid blast crisis of CML) or biological characteristics (three Ph1 -positive ALL) or general medical consideration (one prior autologous transplantation due to high-grade NHL). Median age of the three women and seven men was 40 years (range 25-59). They all had an HLA-identical sibling donor. A detailed list of the clinical characteristics is depicted in Table 1 .
Conditioning and supportive care
High-dose conditioning treatment consisted of 2 × 60 mg/kg CY and 12 Gy TBI. Standard-dose CsA (3 mg/kg/day i.v.) for GVHD prophylaxis started on day −1 and was tapered beyond day +30 until 50% of the starting dose was reached on day +60. The first two patients received short-course MTX in addition (15 mg/m 2 day 1; 10 mg/m 2 days 3 and 6). Selective decontamination of the gut was performed with oral vancomycin, and oral acyclovir was administered to all patients. In the case of CMV viremia acyclovir was stopped and i.v. gancyclovir was initiated. Table 1 Summary of demographic data and characteristics of hematopoietic recovery 
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CD34 + mobilization and preparation of the allograft
The donors received 10 g/kg G-CSF (rmetHu-G-CSF; Filgrastim; Amgen, Munich, Germany) s.c. daily for 5 consecutive days. Large volume leukapheresis was performed on days 4 and 5. In nine patients leukapheresis products were further processed through the Isolex 300i system (Baxter, Unterschleissheim, Germany), while in one patient processing was carried out using the CliniMacs device (Miltenyi Biotec, Bergisch Gladbach, Germany). The leukapheresis products prior to CD34 + selection had a median CD34 + content of 1.3% (range 0.5-3.8%). After selection median CD34
+ content was 86% (range 70-99%). This enrichment, however, was accompanied by a median loss of progenitor cells of 51.6% (range 19-82.65%). CD34 + cells/kg in the CliniMacs processed sample). Rapid engraftment was documented in all patients. The two patients treated with MTX in addition to CsA recovered a few days later than the others. Times to leukocyte and platelet recovery are listed in Table 1 . Full chimerism was proven by PCR of individual short tandem repeats and by X/Y chromosome fluorescence in situ hybridization (FISH) in sex-mismatch transplants (data not shown).
Results
Composition of the allografts and engraftment
T cell add-back, and occurrence of acute and chronic GVHD
Until day +60 none of the patients had clinical signs of aGVHD. At this time point, seven patients received 2 × 10 6
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+ cells/kg taken from the frozen negative fraction of the leukapheresis products. Later on, the concomitant CsA medication was further diminished and after day +80 all patients were off immunosuppressive treatment. On day +90 one patient received a second T cell boost (again 2 × 10 6 CD3 + cells/kg). Four days later, she developed severe, steroid as well as CsA and fludarabine refractory intestinal GVHD grade IV. Ultimately, she succumbed to her GVHD disease at day +142. In three others having received T cell add-back cGVHD of the skin occurred at days +110, +120 and +600, respectively. In two of them, no specific treatment had to be administered, while in one patient the disease progressed to scleroderma despite intensified immunosuppression with steroids, CsA, mycophenolate mofetil, and extracorporal photophoresis. None of the patients who did not receive T cell add-back had developed GVHD within observation times of 55, 365 and 730 days, respectively.
Immune reconstitution and CMV viremia
Until day +60 T and B cell recovery (measured in the peripheral blood as counts of CD19 + , CD3 + , CD4 + , CD8 + and CD56 + cells, respectively) was very slow. In those having T cell add-back, CD3
+ as well as CD4 + and CD8 + cells rose rapidly between day +60 and day +100, but then decreased again to subnormal levels. CD4/CD8 ratio remained lowered in all patients within a median study period of 12 months. A representative case is illustrated in Figure 1 .
Three of the 10 patients became CMV viremic, eg pp65 positive, before day +60. Later on, two patients who received T cell add-back from a CMV IgG-positive donor became pp65-positive. All pp65-positive patients were immediately treated with gancyclovir, and in none of them did overt CMV disease become apparent. Notably, all CMV IgG-negative patients with a IgG-negative donor remained pp65 negative throughout a median observation time of 12 months.
Recurrence of underlying disease and survival
To date, three of the 10 patients have experienced relapse of their leukemia. There were two early relapses of Ph1-positive ALL, one on day +70 (after T cell add-back) and one on day +55 (before T cell add-back). Another relapse occurred late on day +365 (AML, no T cell add-back). All relapsed patients have subsequently died on days +120, +162 and +536, respectively. Another patient died on day +163 from liver failure due to progressive hepatitis B infection which had been present before diagnosis of his AML. Taking into consideration the death due to intestinal GVHD on day +142, in summary five patients are still alive and disease free within a median observation time of 700 days (range 218-1125 days).
Discussion
Graft-versus-host disease is still a major cause of morbidity and of death after allogeneic bone marrow/blood stem cell transplantation. Besides the introduction of new immunosuppressive drugs to prevent and to treat GVHD, attempts have been undertaken to circumvent GVHD by T cell depletion. 1,2 However, T cell depletion has been shown to be associated with an increased risk of graft failure. 4 Moreover, it soon became clear, that at least in CML T cell depletion led to higher relapse rates. 5, 6 These data have been generated in the setting of allogeneic bone marrow transplantation rather than peripheral blood stem cell allografting. Since G-CSF mobilized allografts derived from peripheral blood contain approximately a 16-fold higher number of CD3 + T cells than bone marrow grafts, 8 T cell depletion was of particular interest in view of the continuously increasing use of allogeneic PBSCT. Moreover, some authors have assumed an increased risk of chronic GVHD after allogeneic PBSCT. 9 In our study presented here we could show that peripheral blood-derived allografts with a CD3 + T cell content Ͻ1 × 10 5 cells/kg provided rapid and sustained engraftment in an HLA-identical sibling donor setting. None of the patients developed acute GVHD. It seems questionable, whether any immunosuppression is needed under these circumstances since a T cell dose below 1 × 10 5 CD3 + cells/kg is below the assumed critical threshold for GVHD induction. 7 As our data are in line with the experiences of others 10 T cell depletion appears to be very attractive in performing 'low risk' allogeneic PBSCT. Delayed T cell add-back was performed with the aims of supporting long-term engraftment and contributing to immunocompetence 11 as well as to GVL activity. Of note, to date none of the patients have had secondary graft failure regardless of whether T cells were given or not. Although T cell add-back under the conditions of maintained immune suppression caused no immediate harm to our patients, one patient died after a second T cell boost given without immunosuppressive treatment. Thus, the T cell dose of 2 × 10 6 CD3 + cells/kg is probably too high to be administered as delayed add-back without GVHD prophylaxis. One patient experienced severe cGVHD of the skin 2 months after having his T cell boost. Therefore, further attempts have to be done to separate T cell subpopulations which enable engraftment and provide GVL activity from subpopulations responsible for GVHD. 12 
